Novelion Therapeutics Inc., of Vancouver, British Columbia, reported financial results for the first quarter, with total net revenues of $30 million consisting of net revenues from Myalept (metreleptin), for generalized lipodystrophy, of $14 million – with $11.5 million from U.S. prescriptions – and net revenues of $16 million from sales of Juxtapid (lomitapide), a microsomal triglyceride transfer protein blocker for homozygous familial hypercholesterolemia, with $10.9 million derived from U.S. prescriptions.